13 results on '"Jiskoot, Lize"'
Search Results
2. Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort.
- Author
-
Poos, Jackie M., MacDougall, Amy, van den Berg, Esther, Jiskoot, Lize C., Papma, Janne M., van der Ende, Emma L., Seelaar, Harro, Russell, Lucy L., Peakman, Georgia, Convery, Rhian, Pijnenburg, Yolande A.L., Moreno, Fermin, Sanchez-Valle, Raquel, Borroni, Barbara, Laforce Jr, Robert, Doré, Marie-Claire, Masellis, Mario, Tartaglia, Maria Carmela, Graff, Caroline, and Galimberti, Daniela
- Published
- 2022
- Full Text
- View/download PDF
3. Cognition and gray and white matter characteristics of presymptomatic repeat expansion.
- Author
-
Papma, Janne M., Jiskoot, Lize C., Panman, Jessica L., Dopper, Elise G., den Heijer, Tom, Kaat, Laura Donker, Pijnenburg, Yolande A. L., Meeter, Lieke H., van Minkelen, Rick, Rombouts, Serge A. R. B., van Swieten, John C., and Donker Kaat, Laura
- Published
- 2017
- Full Text
- View/download PDF
4. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
- Author
-
van Sonderen, Agnes, Thijs, Roland D, Coenders, Elias C, Jiskoot, Lize C, Sanchez, Esther, de Bruijn, Marienke A A M, van Coevorden-Hameete, Marleen H, Wirtz, Paul W, Schreurs, Marco W J, Sillevis Smitt, Peter A E, and Titulaer, Maarten J
- Published
- 2016
- Full Text
- View/download PDF
5. Anti-LGI1 encephalitis.
- Author
-
van Sonderen, Agnes, Thijs, Roland D., Coenders, Elias C., Jiskoot, Lize C., Sanchez, Esther, de Bruijn, Marienke A. A. M., van Coevorden-Hameete, Marleen H., Wirtz, Paul W., Schreurs, Marco W. J., Smitt, Peter A. E. Sillevis, and Titulaer, Maarten J.
- Published
- 2016
- Full Text
- View/download PDF
6. Presymptomatic cognitive decline in familial frontotemporal dementia: A longitudinal study.
- Author
-
Jiskoot, Lize C., Dopper, Elise G. P., Heijer, Tom den, Timman, Reinier, van Minkelen, Rick, van Swieten, John C., and Papma, Janne M.
- Published
- 2016
- Full Text
- View/download PDF
7. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia.
- Author
-
Dopper, Elise G P, Rombouts, Serge A R B, Jiskoot, Lize C, Heijer, Tom den, de Graaf, J Roos A, Koning, Inge de, Hammerschlag, Anke R, Seelaar, Harro, Seeley, William W, Veer, Ilya M, van Buchem, Mark A, Rizzu, Patrizia, and van Swieten, John C
- Published
- 2013
- Full Text
- View/download PDF
8. Characterizing the Clinical Features and Atrophy Patterns of -Related Frontotemporal Dementia With Disease Progression Modeling.
- Author
-
Young, Alexandra L., Bocchetta, Martina, Russell, Lucy L., Convery, Rhian S, Peakman, Georgia, Todd, Emily, Cash, David M, Greaves, Caroline V, van Swieten, John, Jiskoot, Lize, Seelaar, Harro, Moreno, Fermin, Sanchez-Valle, Raquel, Borroni, Barbara, Laforce, Robert Jr, Masellis, Mario, Tartaglia, Maria Carmela, Graff, Caroline, Galimberti, Daniela, and Rowe, James B
- Published
- 2021
- Full Text
- View/download PDF
9. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia.
- Author
-
Dopper, Elise G P, Rombouts, Serge A R B, Jiskoot, Lize C, den Heijer, Tom, de Graaf, J Roos A, de Koning, Inge, Hammerschlag, Anke R, Seelaar, Harro, Seeley, William W, Veer, Ilya M, van Buchem, Mark A, Rizzu, Patrizia, and van Swieten, John C
- Published
- 2014
- Full Text
- View/download PDF
10. Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants With Genetic Frontotemporal Dementia.
- Author
-
Schönecker S, Martinez-Murcia FJ, Denecke J, Franzmeier N, Danek A, Wagemann O, Prix C, Wlasich E, Vöglein J, Loosli SV, Brauer A, Górriz Sáez JM, Bouzigues A, Russell LL, Foster PH, Ferry-Bolder E, van Swieten JC, Jiskoot LC, Seelaar H, Sanchez-Valle R, Laforce R Jr, Graff C, Galimberti D, Vandenberghe R, de Mendonça A, Tiraboschi P, Santana I, Gerhard A, Sorbi S, Otto M, Pasquier F, Ducharme S, Butler C, Le Ber I, Finger E, Tartaglia MC, Masellis M, Rowe JB, Synofzik M, Moreno F, Borroni B, Rohrer JD, Priller J, Höglinger GU, and Levin J
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Longitudinal Studies, Atrophy pathology, Behavioral Symptoms etiology, Behavioral Symptoms genetics, Magnetic Resonance Imaging, Mental Disorders genetics, Cohort Studies, Phenotype, Brain diagnostic imaging, Brain pathology, Frontotemporal Dementia genetics, Frontotemporal Dementia diagnostic imaging, Frontotemporal Dementia pathology, Frontotemporal Dementia psychology, C9orf72 Protein genetics, Progranulins genetics, tau Proteins genetics
- Abstract
Background and Objectives: Behavioral and neuropsychiatric symptoms are frequent in patients with genetic frontotemporal dementia (FTD). We aimed to describe behavioral and neuropsychiatric phenotypes in genetic FTD, quantify their temporal association, and investigate their regional association with brain atrophy., Methods: We analyzed data of pathogenic variant carriers in the chromosome 9 open reading frame 72 ( c9orf72 ), progranulin ( GRN ), or microtubule-associated protein tau ( MAPT ) gene from the Genetic Frontotemporal dementia Initiative cohort study that enrolls both symptomatic pathogenic variant carriers and first-degree relatives of known carriers. Principal component analysis was performed to identify behavioral and neuropsychiatric clusters that were compared with respect to frequency and severity between groups. Associations between neuropsychiatric clusters and MRI-assessed atrophy were determined using voxel-based morphometry. We applied linear mixed effects and generalized linear mixed effects models to assess the longitudinal course of symptoms., Results: A total of 522 participants were included: 221 c9orf72 (138 presymptomatic), 213 GRN (157 presymptomatic), and 88 MAPT (62 presymptomatic) pathogenic variant carriers. Principal component analysis revealed 5 phenotypic clusters (67.6% of variance), labeled diverse behavioral, affective, psychotic, euphoric/hypersexual, and tactile hallucinations phenotype. In participants presenting behavioral or neuropsychiatric symptoms, affective symptoms were most frequent across groups (83.6%-88.1%), followed by diverse behavioral symptoms (68.4%-77.9%). In c9orf72 and GRN pathogenic variant carriers, psychotic symptoms (32.0% and 19.4%, respectively) were more frequent than euphoric/hypersexual symptoms (28.7% and 14.2%, respectively), which was the other way around in MAPT pathogenic variant carriers (28.6% and 23.8%). Although diverse behavioral symptoms were associated with gray and white matter frontotemporal atrophy, only a small atrophy cluster in the right thalamus was associated with psychotic symptoms. Euphoric/hypersexual symptoms were associated with atrophy in mesial temporal lobes, basal forebrain structures, and the striatum ( p < 0.05). Estimated time to symptom onset, genetic group, education, and sex influenced behavioral and neuropsychiatric symptoms ( p < 0.05). Particularly, in c9orf72 pathogenic variant carriers, psychotic symptoms may be starting decades before recognition of onset of illness., Discussion: We identified multiple clusters of behavioral and neuropsychiatric symptoms in participants with genetic FTD that relate to distinct cerebral atrophy patterns. Their severity depends on time, affected gene, sex, and education. These clinical-genetic associations can guide diagnostic evaluations and the design of clinical trials for new disease-modifying and preventive treatments.
- Published
- 2024
- Full Text
- View/download PDF
11. Clinical Value of Longitudinal Serum Neurofilament Light Chain in Prodromal Genetic Frontotemporal Dementia.
- Author
-
Giannini LAA, Seelaar H, van der Ende EL, Poos JM, Jiskoot LC, Dopper EGP, Pijnenburg YAL, Willemse EAJ, Vermunt L, Teunissen CE, van Swieten JC, and Meeter LH
- Subjects
- Humans, Biomarkers, C9orf72 Protein genetics, Cohort Studies, Cross-Sectional Studies, Intermediate Filaments, Neurofilament Proteins, tau Proteins genetics, Frontotemporal Dementia diagnostic imaging, Frontotemporal Dementia genetics, Pick Disease of the Brain
- Abstract
Background and Objectives: Elevated serum neurofilament light chain (NfL) is used to identify carriers of genetic frontotemporal dementia (FTD) pathogenic variants approaching prodromal conversion. Yet, the magnitude and timeline of NfL increase are still unclear. Here, we investigated the predictive and early diagnostic value of longitudinal serum NfL for the prodromal conversion in genetic FTD., Methods: In a longitudinal observational cohort study of genetic FTD pathogenic variant carriers, we examined the diagnostic accuracy and conversion risk associated with cross-sectional and longitudinal NfL. Time periods relative to prodromal conversion (>3, 3-1.5, 1.5-0 years before; 0-1.5 years after) were compared with values of participants who did not convert. Next, we modeled longitudinal NfL and MRI volume trajectories to determine their timeline., Results: We included 21 participants who converted (5 chromosome 9 open-reading frame 72 [ C9orf72 ], 10 progranulin [ GRN ], 5 microtubule-associated protein tau [ MAPT ], and 1 TAR DNA-binding protein [TARDBP]) and 61 who did not (20 C9orf72 , 30 GRN , and 11 MAPT ). Participants who converted had higher NfL levels at all examined periods before prodromal conversion (median values 14.0-18.2 pg/mL; betas = 0.4-0.7, standard error [SE] = 0.1, p < 0.046) than those who did not (6.5 pg/mL) and showed further increase 0-1.5 years after conversion (28.4 pg/mL; beta = 1.0, SE = 0.1, p < 0.001). Annualized longitudinal NfL change was only significantly higher in participants who converted (vs. participants who did not) 0-1.5 years after conversion (beta = 1.2, SE = 0.3, p = 0.001). Diagnostic accuracy of cross-sectional NfL for prodromal conversion (vs. nonconversion) was good-to-excellent at time periods before conversion (area under the curve range: 0.72-0.92), improved 0-1.5 years after conversion (0.94-0.97), and outperformed annualized longitudinal change (0.76-0.84). NfL increase in participants who converted occurred earlier than frontotemporal MRI volume change and differed by genetic group and clinical phenotypes. Higher NfL corresponded to increased conversion risk (hazard ratio: cross-sectional = 6.7 [95% CI 3.3-13.7]; longitudinal = 13.0 [95% CI 4.0-42.8]; p < 0.001), but conversion-free follow-up time varied greatly across participants., Discussion: NfL increase discriminates individuals who convert to prodromal FTD from those who do not, preceding significant frontotemporal MRI volume loss. However, NfL alone is limited in predicting the exact timing of prodromal conversion. NfL levels also vary depending on underlying variant-carrying genes and clinical phenotypes. These findings help to guide participant recruitment for clinical trials targeting prodromal genetic FTD., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
12. Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling.
- Author
-
Young AL, Bocchetta M, Russell LL, Convery RS, Peakman G, Todd E, Cash DM, Greaves CV, van Swieten J, Jiskoot L, Seelaar H, Moreno F, Sanchez-Valle R, Borroni B, Laforce R Jr, Masellis M, Tartaglia MC, Graff C, Galimberti D, Rowe JB, Finger E, Synofzik M, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler C, Gerhard A, Levin J, Danek A, Otto M, Sorbi S, Williams SCR, Alexander DC, and Rohrer JD
- Subjects
- Adult, Aged, Atrophy genetics, Atrophy pathology, Brain pathology, Disease Progression, Female, Humans, Image Interpretation, Computer-Assisted methods, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Neuroimaging methods, Frontotemporal Dementia genetics, Frontotemporal Dementia pathology, Machine Learning, tau Proteins genetics
- Abstract
Background and Objective: Mutations in the MAPT gene cause frontotemporal dementia (FTD). Most previous studies investigating the neuroanatomical signature of MAPT mutations have grouped all different mutations together and shown an association with focal atrophy of the temporal lobe. The variability in atrophy patterns between each particular MAPT mutation is less well-characterized. We aimed to investigate whether there were distinct groups of MAPT mutation carriers based on their neuroanatomical signature., Methods: We applied Subtype and Stage Inference (SuStaIn), an unsupervised machine learning technique that identifies groups of individuals with distinct progression patterns, to characterize patterns of regional atrophy in MAPT- associated FTD within the Genetic FTD Initiative (GENFI) cohort study., Results: Eighty-two MAPT mutation carriers were analyzed, the majority of whom had P301L, IVS10+16, or R406W mutations, along with 48 healthy noncarriers. SuStaIn identified 2 groups of MAPT mutation carriers with distinct atrophy patterns: a temporal subtype, in which atrophy was most prominent in the hippocampus, amygdala, temporal cortex, and insula; and a frontotemporal subtype, in which atrophy was more localized to the lateral temporal lobe and anterior insula, as well as the orbitofrontal and ventromedial prefrontal cortex and anterior cingulate. There was one-to-one mapping between IVS10+16 and R406W mutations and the temporal subtype and near one-to-one mapping between P301L mutations and the frontotemporal subtype. There were differences in clinical symptoms and neuropsychological test scores between subtypes: the temporal subtype was associated with amnestic symptoms, whereas the frontotemporal subtype was associated with executive dysfunction., Conclusion: Our results demonstrate that different MAPT mutations give rise to distinct atrophy patterns and clinical phenotype, providing insights into the underlying disease biology and potential utility for patient stratification in therapeutic trials., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
13. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion.
- Author
-
Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, Pijnenburg YAL, Meeter LH, van Minkelen R, Rombouts SARB, and van Swieten JC
- Subjects
- Adult, C9orf72 Protein, Cognitive Dysfunction diagnostic imaging, Diffusion Tensor Imaging, Female, Gray Matter diagnostic imaging, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, White Matter diagnostic imaging, Cognitive Dysfunction pathology, Cognitive Dysfunction physiopathology, DNA Repeat Expansion genetics, Frontotemporal Dementia diagnostic imaging, Frontotemporal Dementia genetics, Frontotemporal Dementia pathology, Frontotemporal Dementia physiopathology, Gray Matter pathology, Proteins genetics, White Matter pathology
- Abstract
Objective: To investigate cognitive function, gray matter volume, and white matter integrity in the presymptomatic stage of chromosome 9 open reading frame 72 repeat expansion ( C9orf72RE )., Methods: Presymptomatic C9orf72RE carriers (n = 18) and first-degree family members without a pathogenic expansion (healthy controls [HC], n = 15) underwent a standardized protocol of neuropsychological tests, T1-weighted MRI, and diffusion tensor imaging within our cohort study of autosomal dominant frontotemporal dementia (FTD). We investigated group differences in cognitive function, gray matter volume through voxel-based morphometry, and white matter integrity by means of tract-based spatial statistics. We correlated cognitive change with underlying gray or white matter., Results: Our data demonstrate lower scores on letter fluency, Stroop card I, and Stroop card III, accompanied by white matter integrity loss in tracts connecting the frontal lobe, the thalamic radiation, and tracts associated with motor functioning in presymptomatic C9orf72RE compared with HC. In a subgroup of C9orf72RE carriers above 40 years of age, we found gray matter volume loss in the thalamus, cerebellum, and parietal and temporal cortex. We found no significant relationship between subtle cognitive decline and underlying gray or white matter., Conclusions: This study demonstrates that a decline in cognitive functioning, white matter integrity, and gray matter volumes are present in presymptomatic C9orf72RE carriers. These findings suggest that neuropsychological assessment, T1-weighted MRI, and diffusion tensor imaging might be useful to identify early biomarkers in the presymptomatic stage of FTD or amyotrophic lateral sclerosis., (© 2017 American Academy of Neurology.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.